PFE catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 20, 2026Sponsor estimate | NCT07821216Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims DataPfizer · Alopecia Areata | PFELead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Nov 29, 2026Sponsor estimate | NCT06641466A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual MigrainePfizer · Menstrual Migraine | PFELead | Phase 3 | Recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT07494656A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in GermanyPfizer · ATTR-CM (Transthyretin Amyloid Cardiomyopathy) | PFELead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 20, 2026Sponsor estimateNo phase registeredNCT07821216Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims DataPfizer · Alopecia AreataActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 29, 2026Sponsor estimatePhase 3NCT06641466A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual MigrainePfizer · Menstrual MigraineRecruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07494656A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in GermanyPfizer · ATTR-CM (Transthyretin Amyloid Cardiomyopathy)Active, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2, 2026Sponsor estimatePhase 3NCT07029711A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataPfizer · Severe Alopecia AreataActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 4, 2026Sponsor estimateNo phase registeredNCT06622109A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six MonthsPfizer · Pneumococcal DiseaseActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 4, 2026Sponsor estimatePhase 1NCT07231991A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver FunctionPfizer · Healthy ParticipantsRecruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 4, 2026Sponsor estimatePhase 3NCT07500506A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease VaccinePfizer · Lyme DiseaseRecruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2026Sponsor estimatePhase 2NCT07228390A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the...Pfizer · Hidradenitis SuppurativaActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2026Sponsor estimatePhase 1NCT07721402A Study to Learn About How Different Forms of Study Medicine Prifetrastat Are Taken Up Into the Blood in Healthy AdultsPfizer · Healthy ParticipantRecruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 11, 2026Sponsor estimatePhase 2NCT04879329A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2Seagen, a wholly owned subsidiary of Pfizer · Urothelial CarcinomaRecruitingPFELeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 12, 2026Sponsor estimatePhase 1NCT06994897A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy AdultsPfizer · HealthyActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 25, 2026Sponsor estimatePhase 2NCT07219615A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.Pfizer · Chronic Spontaneous UrticariaRecruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 3NCT05909397Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerPfizer · Breast CancerActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimateNo phase registeredNCT06495164A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast CancerPfizer · Breast CancerActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimateNo phase registeredNCT06613984Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)Pfizer · COVID-19 VaccinationActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT04553133PF-07104091 as a Single Agent and in Combination TherapyPfizer · Small Cell Lung CancerActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 3NCT05059522Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingPfizer · Advanced MalignanciesActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT05382364Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)Pfizer · Metastatic HER2+ Advanced Breast CancerActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT07906262Efficacy of Rimegepant 75 mg for the Acute Treatment of Migraine: a Bayesian Individual Participant Data Meta-analysis Standardized to...Pfizer · MigraineActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 13, 2027Sponsor estimatePhase 1NCT07725809A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or ObesityPfizer · OverweightActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 18, 2027Sponsor estimatePhase 3NCT05035212Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.Pfizer · Lower Respiratory Tract IllnessActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 24, 2027Sponsor estimateNo phase registeredNCT05032976Korea Comirnaty Post-marketing SurveillancePfizer · COVID-19Active, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 25, 2027Sponsor estimatePhase 3NCT07653100A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreFPfizer · Respiratory Syncytial Virus (RSV)RecruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 27, 2027Sponsor estimatePhase 1NCT07508241A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults...Pfizer · ObesityActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 29, 2027Sponsor estimatePhase 3NCT05911295Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Seagen, a wholly owned subsidiary of Pfizer · Urothelial CarcinomaActive, not recruitingPFELeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 4 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.